Tuesday, November 9, 2021
- 8:30AM-10:30AM
-
Abstract Number: 1554
COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases
Infection-related Rheumatic Disease Poster (1530–1564)- 8:30AM-10:30AM
-
Abstract Number: 1589
COVID-19 Vaccine Hesitancy in Rheumatology Patients
Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)- 8:30AM-10:30AM
-
Abstract Number: 1583
Creation of an Ultrasonographic Scoring System for CPPD Extent: Results from a Delphi Process by the OMERACT US Working Group – CPPD Subgroup
Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)- 8:30AM-10:30AM
-
Abstract Number: 1810
Current Medication Practices and Preferences Among Patients with Psoriatic Arthritis (PsA)
Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)- 8:30AM-10:30AM
-
Abstract Number: 1767
CXCL5 Dampens Inflammation in Murine Lupus by Orchestral Suppression of Effector Cell Proliferation and Leukocyte Extravasation
SLE – Treatment Poster (1732–1772)- 8:30AM-10:30AM
-
Abstract Number: 1508
Decrease of Angiogenic T Cells Associated to the Presence of Interstitial Lung Disease in Patients with Connective Tissue Diseases
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (1507–1515)- 8:30AM-10:30AM
-
Abstract Number: 1879
Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study
Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)- 8:30AM-10:30AM
-
Abstract Number: 1880
Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa
Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)- 8:30AM-10:30AM
-
Abstract Number: 1806
Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA®/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)- 8:30AM-10:30AM
-
Abstract Number: 1576
Development of a Plain Radiographic Scoring System for New Bone Formation in Gout
Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)- 8:30AM-10:30AM
-
Abstract Number: 1526
Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy
Immunological Complications of Therapy Poster (1516–1529)- 8:30AM-10:30AM
-
Abstract Number: 1582
Diagnostic Accuracy and Reliability of Conventional Radiography of the Knee in Calcium Pyrophosphate Deposition Disease by Using New Definitions: An Ancillary Study of the OMERACT Ultrasound – CPPD Group
Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)- 8:30AM-10:30AM
-
Abstract Number: 1872
Differentiating Primary Central Nervous System Vasculitis from Non-inflammatory Intracranial Vasculopathy
Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)- 8:30AM-10:30AM
-
Abstract Number: 1830
Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis